EP3976068A4 - Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t - Google Patents

Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t Download PDF

Info

Publication number
EP3976068A4
EP3976068A4 EP20814747.0A EP20814747A EP3976068A4 EP 3976068 A4 EP3976068 A4 EP 3976068A4 EP 20814747 A EP20814747 A EP 20814747A EP 3976068 A4 EP3976068 A4 EP 3976068A4
Authority
EP
European Patent Office
Prior art keywords
cytokin
cocktails
cell subsets
selective expansion
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20814747.0A
Other languages
German (de)
English (en)
Other versions
EP3976068A1 (fr
Inventor
Catherine Mary BOLLARD
Patrick Hanley
Christopher LAZARSKI
Michael Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens National Medical Center Inc
Original Assignee
Childrens National Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens National Medical Center Inc filed Critical Childrens National Medical Center Inc
Publication of EP3976068A1 publication Critical patent/EP3976068A1/fr
Publication of EP3976068A4 publication Critical patent/EP3976068A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP20814747.0A 2019-05-31 2020-06-01 Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t Pending EP3976068A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855889P 2019-05-31 2019-05-31
PCT/US2020/035618 WO2020243729A1 (fr) 2019-05-31 2020-06-01 Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t

Publications (2)

Publication Number Publication Date
EP3976068A1 EP3976068A1 (fr) 2022-04-06
EP3976068A4 true EP3976068A4 (fr) 2023-08-09

Family

ID=73553344

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20814747.0A Pending EP3976068A4 (fr) 2019-05-31 2020-06-01 Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t

Country Status (2)

Country Link
EP (1) EP3976068A4 (fr)
WO (1) WO2020243729A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
IL272635B2 (en) 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use
EP4259163A2 (fr) * 2020-12-09 2023-10-18 Tevogen Bio Inc. Lymphocytes t spécifiques d'un virus et procédés de traitement et de prévention d'infections virales
WO2022195096A1 (fr) * 2021-03-19 2022-09-22 Charité - Universitätsmedizin Berlin Peptide et procédé d'analyse directe de réponses immunitaires au sras-cov-2
WO2022212505A1 (fr) * 2021-03-30 2022-10-06 Arizona Board Of Regents On Behalf Of Arizona State University Production optimale de particules pseudovirales (vlp) du sars-cov-2 produites dans des cellules de mammifère
EP4395805A1 (fr) * 2021-09-03 2024-07-10 International N&H Denmark ApS Antigènes microbiens à réactivité croisée destinés à être utilisés dans la stimulation de lymphocytes t
CN114578048B (zh) * 2021-12-22 2023-08-08 重庆医科大学附属儿童医院 一种t淋巴细胞发育亚群免疫分型的方法和试剂盒
GR1010557B (el) * 2022-05-04 2023-10-16 Νοσοκομειο Γεωργιος Παπανικολαου, Sars-cov-2-ειδικα τ λεμφοκυτταρα για θεραπεια της covid-19
CN116694828A (zh) * 2023-08-01 2023-09-05 北京大学人民医院 检测试剂的应用、cd3+t细胞抗感染能力评估方法及产品

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119947A1 (fr) * 2012-02-09 2013-08-15 Baylor College Of Medicine Mélange de peptides pour produire des ctlmultiviraux avec une large spécificité
WO2017049291A1 (fr) * 2015-09-18 2017-03-23 Baylor College Of Medicine Identification d'antigène immunogène à partir d'un pathogène et corrélation avec l'efficacité clinique
WO2017075571A1 (fr) * 2015-10-30 2017-05-04 Children's National Medical Center Génération de lymphocytes t spécifiques contre l'antigène du vph à partir d'une population de lymphocytes t naïfs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102625832A (zh) * 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
EP2532740A1 (fr) * 2011-06-11 2012-12-12 Michael Schmück Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
WO2016183350A1 (fr) * 2015-05-13 2016-11-17 Terumobct, Inc. Expansion cellulaire
MX2019000180A (es) * 2016-06-28 2019-11-05 Geneius Biotechnology Inc Composiciones de células t para la inmunoterapia.
US10960070B2 (en) * 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119947A1 (fr) * 2012-02-09 2013-08-15 Baylor College Of Medicine Mélange de peptides pour produire des ctlmultiviraux avec une large spécificité
WO2017049291A1 (fr) * 2015-09-18 2017-03-23 Baylor College Of Medicine Identification d'antigène immunogène à partir d'un pathogène et corrélation avec l'efficacité clinique
WO2017075571A1 (fr) * 2015-10-30 2017-05-04 Children's National Medical Center Génération de lymphocytes t spécifiques contre l'antigène du vph à partir d'une population de lymphocytes t naïfs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020243729A1 *

Also Published As

Publication number Publication date
WO2020243729A1 (fr) 2020-12-03
EP3976068A1 (fr) 2022-04-06

Similar Documents

Publication Publication Date Title
EP3976068A4 (fr) Cocktails de cytokines pour expansion sélective de sous-ensembles de lymphocytes t
DK3897833T3 (da) Hæmmere af APOL1 og fremgangsmåder til anvendelse heraf
EP4231561C0 (fr) Procédés de prise en charge de retransmission de liaison latérale
EP3857756C0 (fr) Signalisation destinée à une répétition
DK3507386T3 (da) Fremgangsmåder og indretning, der øger effektiviteten af sekvensering med binding
HUE059594T2 (hu) Hírvivõ RNS tisztítására szolgáló eljárások
IL286233A (en) Methods and systems for sequence calling
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
IL268944A (en) A method for replicating or amplifying circular DNA
EP3464689A4 (fr) Système et procédé de croissance des nitrures du groupe iiia
DK3607050T3 (da) Ex vivo-dyrkningssystem og metoder til brugen af samme
MA55478A (fr) Inhibiteurs bicycliques de hpk1
MA55477A (fr) Inhibiteurs de hpk1
EP3868889A4 (fr) Procédé d'activation/prolifération de lymphocytes t
DK3606929T3 (da) Beta-nicotinat-ester-nukleotider og fremgangsmåder til fremstilling af samme
EP3864811C0 (fr) Méthode de réduction du rapport de puissance de crête sur moyen des signaux dm-rs
EP3752278C0 (fr) Méthodes pour la réduction de biofilm et de sporesà partir de membranes
IL280772A (en) Multiplex detection of nucleic acids
DK3630772T3 (da) Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere
DK3120055T3 (da) Membran og fremgangsmåde til fremstilling deraf
DK3277742T3 (da) Fluorescerende siloxanelastomer, fremgangsmåde til fremstilling af denne og anvendelsen
EP3458448A4 (fr) Procédés d'utilisation d'inhibiteurs de fasn
DK3307878T3 (da) Fremgangsmåder til fremstilling og oprensning af nukleinsyreholdige sammensætninger
EP3634266A4 (fr) Système d'élimination de fécalithe

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230707

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20230704BHEP

Ipc: C07K 14/54 20060101ALI20230704BHEP

Ipc: C07K 14/005 20060101ALI20230704BHEP

Ipc: A61K 39/215 20060101ALI20230704BHEP

Ipc: A61K 39/12 20060101ALI20230704BHEP

Ipc: A61K 38/00 20060101ALI20230704BHEP

Ipc: A61K 35/17 20150101AFI20230704BHEP